Pharma & Biotech
Valneva’s Binary Outlook: A Broken Commercial Business Versus a Potentially Blockbuster Pipeline
For investors in Valneva, the gap between hope and reality has rarely been wider. The French biotech’s stock ended last...
Ocugen’s 673% Analyst Upside Hinges on a Tight Window of Clinical Data and Regulatory Submissions
A €10 price target with the stock trading at €1.29. That 673% gap isn't a typo — it's the distance...
Novo Nordisk Tests Resistance Near Overbought as Buyback and Oral Wegovy Drive Sentiment
Novo Nordisk closed the week at €43.32, adding 1.29% on Friday alone, as a wave of analyst upgrades and a...
Novo Nordisk Deploys Tiered Pricing and Weekly Insulin to Broaden GLP-1 Reach as Medicare Uptake Lags
Medicare Part D prescriptions for Wegovy surged nearly 600 percent within six months of the FDA’s March 2024 cardiovascular risk...
Ocugen’s Modifier Gene Therapy Targets Dozens of Blindness-Causing Mutations with One Drug
A single drug that could treat inherited blindness regardless of which gene is broken — that is the audacious promise...
Low-Volume Rally Drives Outlook Therapeutics 127% Higher Ahead of FDA Verdict
Outlook Therapeutics shares have more than doubled – and then some – over the past month, but the price action...
Bayer’s Ruveon Overhaul and Analyst Divergence Signal a Pivotal Moment After a 40% Rally
Bayer has moved decisively to reshape its US glyphosate operations, folding the business into a newly created entity called Ruveon...
BioNTech’s Oncology Ambition Faces a Trio of Tests: Clinical Data, Founder Departure, and Deep Cost-Cutting
BioNTech is entering a period where scientific validation, financial discipline, and leadership transition all converge. The stock closed Tuesday at...
Novo Nordisk Expands Oral Wegovy to UK and New Liver Indication, Implant Study on Horizon
Novo Nordisk is extending its oral Wegovy franchise across multiple fronts simultaneously, with a UK launch, a fresh liver fibrosis...
Two Final Events Hold the Key for Sellas Life Sciences as the Stock Races Ahead of Its Fundamentals
Sellas Life Sciences has turned into a live referendum on a single clinical dataset, with the stock’s eye-popping 594% annual...
Popular News
-
SunHydrogen Set for European Debut with Groundbreaking Technology
-
Walgreens Implements Deep Restructuring Following Private Buyout
-
Exploring the Rise of AI in Empowering Business and Personal Growth: Trends and Innovations
-
Trade Desk Shares Face Mounting Pressure as Tariff Warnings Materialize
-
Kraft Heinz Stock: A Contradiction in Market Sentiment
